McNicholas BA, Rooney GM, Laffey JG.
Curr Opin Crit Care. 2018 Feb;24(1):41-48. doi: 10.1097/MCC.0000000000000473. Review.
PMID: 29135617
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.